A state-of-the-art engineering approach toward improving the neutralizing activity of a cross-reactive nanobody, previously generated against the original SARS virus, showed it can be an attractive ...
In a recent study published in Science Immunology, researchers investigated the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron's immune escape mechanisms ...
Invivyd, Inc. announced new in vitro data demonstrating that its investigational monoclonal antibody PEMGARDA™ (pemivibart) continues to show consistent neutralizing activity against the dominant SARS ...
WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today provided ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve at a rapid pace, generating new variants that arouse concern. Variants that were first detected in California (B.1.429 ...
The neutralizing activity of all serum samples was tested against the B.1.429 variant and a variant of concern that first emerged in South Africa (B.1.351, also called 20H/501Y.V2). We compared this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results